Home » Newsletters » BioWorld Science

BioWorld Science

July 5, 2011

View Archived Issues

Zealand Pharma presents new preclinical data on ZP-3022 and ZP-2929 in models of diabetes/obesity

AN-6414 is safe and improves symptoms of arthritis in preclinical studies

Cannabinoid CB1 receptor inverse agonist JD-5037 has no effects on CNS

Advinus Therapeutics and Merck & Co. discover new small-molecule SUCNR1 receptor antagonist

AR-00472159 has anti-inflammatory activity in mice with experimental colitis

Linagliptin approved in Japan for type 2 diabetes

NeuroSearch provides update on planning of phase III program for Huntexil in Huntington's disease

Novel free fatty acid FFA2 receptor agonists patented by Euroscreen

Merck KGaA files with EMA to extend Rebif indication to patients with early signs of MS

Unversity of Georgia presents new HIV integrase inhibitors

Japanese marketing approval granted for Betanis for overactive bladder

Targacept claims new nicotinic acetylcholine alpha4beta2 receptor ligands

Janssen obtains Japanese manufacturing and marketing license for Simponi in RA

Roche and Siena Biotech present novel beta-secretase inhibitors

Takeda receives Japanese approval for Liovel NDA in type 2 diabetes

Medivir and Meda renegotiate terms of commercial partnership for Xerese

Researchers at Shionogi disclose new beta-secretase 1 inhibitors

Lantheus initiates phase III trial of PET imaging with flurpiridaz F-18 for CAD

FDA accepts for filing Corcept Therapeutics' Corlux NDA for Cushing's syndrome

Ono Pharmaceutical's Corebeta approved in Japan to improve quality of coronary CT angiography images

Novartis halts phase III study of Afinitor in advanced breast cancer after meeting primary endpoint

ALK-Abello provides update on North American allergy vaccine partnership with Merck & Co.

Antisense Therapeutics grants exclusive option to license anticancer compound ATL-1101 to Afandin

Medicago reports encouraging phase II results on H5N1 vaccine

FDA grants Advaxis pre-IND meeting for prostate cancer immunotherapy Advaxis PSA

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Medline raises $6.3B in fourth med-tech IPO of December
BioWorld MedTech
Medline Inc. returned to the public markets with a blockbuster IPO of $6.26 billion, reportedly this year’s largest IPO globally. The upsized offering of more...
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
Vitesse finesse pays off: DBV wins in peanut allergy phase III
BioWorld
DBV Technologies SA’s pivotal phase III trial with the Viaskin Peanut allergy patch came through for the company, and officials plan a BLA filing with the U.S....
Acryl raises $28M IPO, aiming to bridge medical divide with AI
BioWorld MedTech
Acryl Inc. debuted on South Korea’s Kosdaq Dec. 16, raising ₩42.12 billion ($28.5 million) in an IPO. Shares (KOSDAQ:0007C0) closed at ₩67,000 on the first day,...